Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat

Epilepsia

Volumn 50, Issue 4, 2009, Pages 721-730

  Ferraro, Giuseppe ^a   Sardo, Pierangelo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cholecystokinin 8 sulfate; Control; Partial epilepsy; Rat; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; BICUCULLINE; CHOLECYSTOKININ OCTAPEPTIDE; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DENTATE GYRUS; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; ELECTROSTIMULATION; EVOKED RESPONSE; GABAERGIC TRANSMISSION; IONTOPHORESIS; LATENT PERIOD; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; BICUCULLINE; CONVULSANTS; DENTATE GYRUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION; EPILEPSY, COMPLEX PARTIAL; EVOKED POTENTIALS; MALE; NOOTROPIC AGENTS; RATS; RATS, WISTAR; REACTION TIME; SINCALIDE; VIGABATRIN;

EID: 63849095909     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01956.x     Document Type: Article

References (40)

1. Acosta GB 1998) Administration of cholecystokinin sulphated octapeptide (CCK-8S) induces changes on rat amino acid tissue levels and on a behavioral test for anxiety. Gen Pharmacol 31 : 637 641.
2. Acosta GB 2001) A possible interaction between CCKergic and GABAergic systems in the rat brain. Comp Biochem Physiol C 128 : 11 17.
3. Bough KJ, Schwartzkroin PA, Rho JM 2003) Calorie restriction and ketogenic diet diminish neuronal excitability in rat dentate gyrus in vivo. Epilepsia 44 : 752 760.
4. Conway M, Cubbidge RP, Hosking SL 2008) Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 49 : 108 116.
5. Day HE, McKnight AT, Poat JA, Hughes J 1994) Evidence that cholecystokinin induces immediate early gene expression in the brain-stem, hypothalamus and amygdala of the rat. Neuropharmacology 33 : 719 727.
6. Deng PY, Lei S 2006) Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats. J Physiol 572 : 425 442.
7. Eigyo M, Katsuura G, Shintaku H, Shinohara S, Katoh A, Shiomi T, Matsushita A 1992) Systemic administration of a cholecystokinin analogue, ceruletide, protects against ischemia-induced neurodegeneration in gerbils. Eur J Pharmacol 214 : 149 158.
8. Ferraro G, Sardo P 2004) Nitric oxide and brain hyperexcitability. In Vivo 18 : 357 366.
9. Fetissov SO, Jacoby AS, Brumovsky PR, Shine J, Iismaa TP, Hokfelt T 2003) Altered hippocampal expression of neuropeptides in seizure-prone GALR1 knockout mice. Epilepsia 44 : 1022 1033.
10. Fourny D, Escrieut C, Archer E, Galès C, Gigoux V, Maigret B, Moroder L, Silvente-Poirot S, Martinez J, Fehrentz JA, Pradayrol L 2002) Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists. Pharmacol Toxicol 91 : 313 320.
11. Homayoun H, Dehpour AR 2004) Differential contribution of cholecystokinin receptors to stress-induced modulation of seizure and nociception thresholds in mice. Pharmacol Biochem Behav 78 : 209 215.
12. Homayoun H, Khavandgar S, Dehpour AR 2002) The involvement of endogenous opioids and nitricoxidergic pathway in the anticonvulsant effects of foot-shock stress in mice. Epilepsy Res 49 : 131 142.
13. Izumi Y, Ishikawa M, Benz AM, Izumi M, Zorumski CF, Thio LL 2004) Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 45 : 1043 1048.
14. Kwan P, Sills GJ, Brodie MJ 2001) The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 90 : 21 34.
15. Legido A, Adler MW, Karkanias C, Geller EB, Bradley E, Greenstein JI, Grover WD 1995) Cholecystokinin potentiates morphine anticonvulsant action through CCK-A and CCK-B receptor. Neuropeptides 28 : 107 113.
16. Lothman EW, Stringer JL, Bertram EH 1992) The dentate gyrus as a control point for seizures in the hippocampus and beyond. Epilepsy Res 7 : 301 313.
17. Moran TH, Schwartz GJ 1994) Neurobiology of cholecystokinin. Crit Rev Neurobiol 9 : 1 28.
18. Mosher JT, Birkemo LS, Johnson MF, Ervin GN 1998) Sulphated cholecystokinin (26-33) induces mild taste aversion conditioning in rats when administered by three different routes. Peptides 19 : 849 857.
19. Nagahama H 1989) Acute and long-lasting effects of peripheral injection of coerulein and CCK-8 on the central GABAergic system in mice. Peptides 10 : 1247 1251.
20. Paxinos G, Watson C 1986) The rat brain in stereotaxic co-ordinates. Academic Press, San Diego, IL, U.S.A.
21. Ratnaraj N, Patsalos PN 1998) A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in the serum. Drug Monit 20 : 430 434.
22. Raybould HE 2007) Mechanisms of CCK signalling from gut to brain. Curr Opin Pharmacol 7 : 570 574.
23. Reibel S, Benmaamar R, Larmet Y, Kalra SP, Marescaux C, Depaulis A 2003) Neuropeptide Y delays hippocampal kindling in the rat. Hippocampus 13 : 557 560.
24. Roberts JE 2001) Ocular phototoxicity. J Photochem Photobiol 64 : 136 143.
25. Sardo P, Ferraro G 2007) Modulatory effects of nitric oxide-active drugs on the anticonvulsant activity of lamotrigine in an experimental model of partial complex epilepsy in the rat. BMC Neurosci 8 : 47 53.
26. Serra M, Dazzi L, Cagetti E, Chessa MF, Pisu MG, Sanna A, Biggio G 1997) Effect of pentylenetetrazole-induced kindling on acetylcholine release in the hippocampus of freely moving rats. J Neurochem 68 : 313 318.
27. Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie MJ 2003) Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44 : 886 892.
28. Stringer JL, Lothman EW 1990a) Maximal dentate activation: a tool to screen compounds for activity against limbic seizures. Epilepsy Res 5 : 169 176.
29. Stringer JL, Lothman EW 1990b) Pharmacological evidence indicating a role of GABAergic system in termination of limbic seizures. Epilepsy Res 7 : 197 204.
30. Stringer JL, Lothman EW 1990c) A1 adenosinergic modulation alters the duration of maximal dentate activation. Neurosci Lett 118 : 231 234.
31. Stringer JL, Lothman EW 1992) Reverberatory seizure discharges in hippocampal-parahippocampal circuits. Exp Neurol 116 : 198 203.
32. Tirassa P, Aloe L, Stenfors C, Turrini P, Lundeberg T 1999) Cholecystokinin-8 protects central cholinergic neurons against fimbria-fornix lesion through the up-regulation of nerve growth factor synthesis. Proc Natl Acad Sci USA 96 : 6473 6477.
33. Tirassa P, Manni L, Aloe L, Lundeberg T 2002) Cholecystokinin-8 and nerve growth factor: two endogenous molecules working for the upkeep and repair of the nervous system. Curr Drug Target CNS Neurol Disord 1 : 495 510.
34. Tirassa P, Costa N, Aloe L 2005) CCK-8 prevents the development of kindling and regulates the GABA and NPY expression in the hippocampus of pentylenetetrazole (PTZ)-treated adult rats. Neuropharmacology 48 : 732 742.
35. Tong X, Ratnaraj N, Patsalos PN 2007) The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid. Seizure 16 : 43 49.
36. Treiman DM 2001) GABAergic mechanisms in epilepsy. Epilepsia 42 : 8 12.
37. Wheless JW, Ramsay RE, Collins SD 2007) Vigabatrin. Neurotherapeutics 4 : 163 172.
38. White HS 1997) Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 38 : 9 17.
39. Wild JM, Ahn HS, Baulac M, Bursztyn J, Chiron C, Gandolfo E, Safran AB, Schiefer U, Perucca E 2007) Vigabatrin and epilepsy: lessons learned. Epilepsia 48 : 1318 1327.
40. Wu Y, Wang W, Richerson GB 2003) Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. J Neurophysiol 89 : 2021 2034.